Botulinum  ||| S:0 E:10 ||| JJ
toxin  ||| S:10 E:16 ||| NN
A ||| S:16 E:17 ||| NN
:  ||| S:17 E:19 ||| :
is  ||| S:19 E:22 ||| VBZ
it  ||| S:22 E:25 ||| PRP
really  ||| S:25 E:32 ||| RB
that  ||| S:32 E:37 ||| IN
fragile  ||| S:37 E:45 ||| VBG
a  ||| S:45 E:47 ||| DT
molecule ||| S:47 E:55 ||| NN
?  ||| S:55 E:57 ||| .
Botulinum  ||| S:57 E:67 ||| JJ
toxin  ||| S:67 E:73 ||| NN
A  ||| S:73 E:75 ||| DT
is  ||| S:75 E:78 ||| VBZ
considered  ||| S:78 E:89 ||| VBN
to  ||| S:89 E:92 ||| TO
be  ||| S:92 E:95 ||| VB
an  ||| S:95 E:98 ||| DT
extremely  ||| S:98 E:108 ||| RB
fragile  ||| S:108 E:116 ||| JJ
molecule ||| S:116 E:124 ||| NN
,  ||| S:124 E:126 ||| ,
with  ||| S:126 E:131 ||| IN
recommended  ||| S:131 E:143 ||| JJ
usage  ||| S:143 E:149 ||| NN
of  ||| S:149 E:152 ||| IN
some  ||| S:152 E:157 ||| DT
reconstituted  ||| S:157 E:171 ||| JJ
botulinum  ||| S:171 E:181 ||| JJ
toxin  ||| S:181 E:187 ||| NN
A  ||| S:187 E:189 ||| DT
formulations  ||| S:189 E:202 ||| NN
within  ||| S:202 E:209 ||| IN
4  ||| S:209 E:211 ||| CD
hours  ||| S:211 E:217 ||| NNS
of  ||| S:217 E:220 ||| IN
reconstitution ||| S:220 E:234 ||| NN
.  ||| S:234 E:236 ||| .
Extreme  ||| S:236 E:244 ||| JJ
caution  ||| S:244 E:252 ||| NN
is  ||| S:252 E:255 ||| VBZ
recommended  ||| S:255 E:267 ||| VBN
to  ||| S:267 E:270 ||| TO
avoid  ||| S:270 E:276 ||| VB
agitation  ||| S:276 E:286 ||| VBN
of  ||| S:286 E:289 ||| IN
the  ||| S:289 E:293 ||| DT
vial ||| S:293 E:297 ||| NN
.  ||| S:297 E:299 ||| .
To  ||| S:299 E:302 ||| TO
determine  ||| S:302 E:312 ||| VB
whether  ||| S:312 E:320 ||| IN
the  ||| S:320 E:324 ||| DT
effect  ||| S:324 E:331 ||| NN
of  ||| S:331 E:334 ||| IN
reconstituted  ||| S:334 E:348 ||| JJ
botulinum  ||| S:348 E:358 ||| JJ
toxin  ||| S:358 E:364 ||| NN
A  ||| S:364 E:366 ||| DT
is  ||| S:366 E:369 ||| VBZ
maintained  ||| S:369 E:380 ||| VBN
even  ||| S:380 E:385 ||| RB
when  ||| S:385 E:390 ||| WRB
it  ||| S:390 E:393 ||| PRP
is  ||| S:393 E:396 ||| VBZ
agitated  ||| S:396 E:405 ||| VBN
vigorously ||| S:405 E:415 ||| RB
.  ||| S:415 E:417 ||| .
Experimental ||| S:417 E:429 ||| NNP
,  ||| S:429 E:431 ||| ,
comparative ||| S:431 E:442 ||| JJ
,  ||| S:442 E:444 ||| ,
animal  ||| S:444 E:451 ||| JJ
study ||| S:451 E:456 ||| NN
.  ||| S:456 E:458 ||| .
Sixty-four  ||| S:458 E:469 ||| JJ
white  ||| S:469 E:475 ||| JJ
Swiss  ||| S:475 E:481 ||| JJ
Webster  ||| S:481 E:489 ||| NNP
mice ||| S:489 E:493 ||| NNS
,  ||| S:493 E:495 ||| ,
aged  ||| S:495 E:500 ||| VBN
2  ||| S:500 E:502 ||| CD
to  ||| S:502 E:505 ||| TO
4  ||| S:505 E:507 ||| CD
weeks ||| S:507 E:512 ||| NNS
,  ||| S:512 E:514 ||| ,
arranged  ||| S:514 E:523 ||| VBN
in  ||| S:523 E:526 ||| IN
eight  ||| S:526 E:532 ||| CD
separate  ||| S:532 E:541 ||| JJ
groups ||| S:541 E:547 ||| NNS
.  ||| S:547 E:549 ||| .
Reconstituted  ||| S:549 E:563 ||| NNP
onabotulinumtoxinA  ||| S:563 E:582 ||| NNP
( ||| S:582 E:583 ||| -LRB-
2.5  ||| S:583 E:587 ||| CD
U ||| S:587 E:588 ||| NNP
/ ||| S:588 E:589 ||| CD
0.1  ||| S:589 E:593 ||| CD
mL ||| S:593 E:595 ||| NN
)  ||| S:595 E:597 ||| -RRB-
was  ||| S:597 E:601 ||| VBD
placed  ||| S:601 E:608 ||| VBN
securely  ||| S:608 E:617 ||| RB
in  ||| S:617 E:620 ||| IN
a  ||| S:620 E:622 ||| DT
battery-operated  ||| S:622 E:639 ||| JJ
mechanized  ||| S:639 E:650 ||| JJ
apparatus ||| S:650 E:659 ||| NN
.  ||| S:659 E:661 ||| .
The  ||| S:661 E:665 ||| DT
apparatus  ||| S:665 E:675 ||| NN
with  ||| S:675 E:680 ||| IN
the  ||| S:680 E:684 ||| DT
vial  ||| S:684 E:689 ||| NN
was  ||| S:689 E:693 ||| VBD
placed  ||| S:693 E:700 ||| VBN
in  ||| S:700 E:703 ||| IN
the  ||| S:703 E:707 ||| DT
refrigerator ||| S:707 E:719 ||| NN
,  ||| S:719 E:721 ||| ,
and  ||| S:721 E:725 ||| CC
the  ||| S:725 E:729 ||| DT
apparatus  ||| S:729 E:739 ||| NN
continuously  ||| S:739 E:752 ||| RB
inverted  ||| S:752 E:761 ||| VBN
and  ||| S:761 E:765 ||| CC
straightened  ||| S:765 E:778 ||| VBG
the  ||| S:778 E:782 ||| DT
onabotulinumtoxinA  ||| S:782 E:801 ||| JJ
vial  ||| S:801 E:806 ||| NN
30  ||| S:806 E:809 ||| CD
times  ||| S:809 E:815 ||| NNS
a  ||| S:815 E:817 ||| DT
minute ||| S:817 E:823 ||| NN
.  ||| S:823 E:825 ||| .
Eight  ||| S:825 E:831 ||| CD
mice  ||| S:831 E:836 ||| NNS
were  ||| S:836 E:841 ||| VBD
each  ||| S:841 E:846 ||| DT
injected  ||| S:846 E:855 ||| JJ
intraperitoneally  ||| S:855 E:873 ||| NN
with  ||| S:873 E:878 ||| IN
1  ||| S:878 E:880 ||| CD
U  ||| S:880 E:882 ||| NNP
of  ||| S:882 E:885 ||| IN
the  ||| S:885 E:889 ||| DT
agitated  ||| S:889 E:898 ||| JJ
onabotulinumtoxinA  ||| S:898 E:917 ||| NN
on  ||| S:917 E:920 ||| IN
days  ||| S:920 E:925 ||| NNS
1 ||| S:925 E:926 ||| CD
,  ||| S:926 E:928 ||| ,
3 ||| S:928 E:929 ||| CD
,  ||| S:929 E:931 ||| ,
5 ||| S:931 E:932 ||| CD
,  ||| S:932 E:934 ||| ,
7 ||| S:934 E:935 ||| CD
,  ||| S:935 E:937 ||| ,
14 ||| S:937 E:939 ||| CD
,  ||| S:939 E:941 ||| ,
21 ||| S:941 E:943 ||| CD
,  ||| S:943 E:945 ||| ,
28 ||| S:945 E:947 ||| CD
,  ||| S:947 E:949 ||| ,
and  ||| S:949 E:953 ||| CC
42 ||| S:953 E:955 ||| CD
,  ||| S:955 E:957 ||| ,
to  ||| S:957 E:960 ||| TO
evaluate  ||| S:960 E:969 ||| VB
the  ||| S:969 E:973 ||| DT
efficacy  ||| S:973 E:982 ||| NN
of  ||| S:982 E:985 ||| IN
the  ||| S:985 E:989 ||| DT
continuously  ||| S:989 E:1002 ||| JJ
agitated  ||| S:1002 E:1011 ||| JJ
onabotulinumtoxinA ||| S:1011 E:1029 ||| NN
.  ||| S:1029 E:1031 ||| .
Death  ||| S:1031 E:1037 ||| NN
of  ||| S:1037 E:1040 ||| IN
the  ||| S:1040 E:1044 ||| DT
mice ||| S:1044 E:1048 ||| NNS
,  ||| S:1048 E:1050 ||| ,
demonstrating  ||| S:1050 E:1064 ||| VBG
efficacy  ||| S:1064 E:1073 ||| NN
of  ||| S:1073 E:1076 ||| IN
the  ||| S:1076 E:1080 ||| DT
onabotulinumtoxinA  ||| S:1080 E:1099 ||| JJ
molecule ||| S:1099 E:1107 ||| NN
.  ||| S:1107 E:1109 ||| .
Half  ||| S:1109 E:1114 ||| NN
of  ||| S:1114 E:1117 ||| IN
each  ||| S:1117 E:1122 ||| DT
group  ||| S:1122 E:1128 ||| NN
of  ||| S:1128 E:1131 ||| IN
mice  ||| S:1131 E:1136 ||| NNS
( ||| S:1136 E:1137 ||| -LRB-
4 ||| S:1137 E:1138 ||| CD
/ ||| S:1138 E:1139 ||| CD
8  ||| S:1139 E:1141 ||| CD
mice ||| S:1141 E:1145 ||| NNS
)  ||| S:1145 E:1147 ||| -RRB-
died  ||| S:1147 E:1152 ||| VBD
within  ||| S:1152 E:1159 ||| IN
48  ||| S:1159 E:1162 ||| CD
hours  ||| S:1162 E:1168 ||| NNS
of  ||| S:1168 E:1171 ||| IN
the  ||| S:1171 E:1175 ||| DT
injection  ||| S:1175 E:1185 ||| NN
( ||| S:1185 E:1186 ||| -LRB-
range  ||| S:1186 E:1192 ||| NN
16-48  ||| S:1192 E:1198 ||| CD
hours ||| S:1198 E:1203 ||| NNS
) ||| S:1203 E:1204 ||| -RRB-
.  ||| S:1204 E:1206 ||| .
The  ||| S:1206 E:1210 ||| DT
effect  ||| S:1210 E:1217 ||| NN
of  ||| S:1217 E:1220 ||| IN
botulinum  ||| S:1220 E:1230 ||| JJ
toxin  ||| S:1230 E:1236 ||| NN
type  ||| S:1236 E:1241 ||| NN
A  ||| S:1241 E:1243 ||| DT
is  ||| S:1243 E:1246 ||| VBZ
maintained  ||| S:1246 E:1257 ||| VBN
even  ||| S:1257 E:1262 ||| RB
when  ||| S:1262 E:1267 ||| WRB
it  ||| S:1267 E:1270 ||| PRP
is  ||| S:1270 E:1273 ||| VBZ
agitated  ||| S:1273 E:1282 ||| VBN
vigorously  ||| S:1282 E:1293 ||| RB
for  ||| S:1293 E:1297 ||| IN
up  ||| S:1297 E:1300 ||| RB
to  ||| S:1300 E:1303 ||| TO
6  ||| S:1303 E:1305 ||| CD
weeks ||| S:1305 E:1310 ||| NNS
.  ||| S:1310 E:1312 ||| .
The  ||| S:1312 E:1316 ||| DT
authors  ||| S:1316 E:1324 ||| NNS
have  ||| S:1324 E:1329 ||| VBP
indicated  ||| S:1329 E:1339 ||| VBN
no  ||| S:1339 E:1342 ||| DT
significant  ||| S:1342 E:1354 ||| JJ
interest  ||| S:1354 E:1363 ||| NN
with  ||| S:1363 E:1368 ||| IN
commercial  ||| S:1368 E:1379 ||| JJ
supporters ||| S:1379 E:1389 ||| NNS
.  ||| S:1389 E:1391 ||| .
